$ 734.35
Key Takeaways
Risk factor
Very vulnerable to price shocks
Profitability factor
Greatly overvalued vs peers
About
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/E
Target Price
The average target price of ARGX is 848 and suggests 15% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
